Greenwich LifeSciences is a clinical-stage biopharmaceutical company with no commercial revenue, so its quarterly results are driven almost entirely by spending on its lead candidate, GLSI-100 — an immunotherapy designed to prevent breast cancer recurrence. The company is running the Flamingo-01 Phase III trial and expanding its footprint into Europe, with plans to open up to 150 sites globally. For investors, this report matters less for top-line figures and more for the pace of trial investment, the company's cash runway, and whether management can fund development without excessive dilution. Prior quarters showed widening losses as trial costs accelerated, and this Q3 2026 report confirms that trend while underscoring the importance of near-term financing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the third quarter ended September 30, 2026, GLSI reported a net loss of $5.81 million, compared with $3.71 million in the year-ago quarter. Basic and diluted loss per share from continuing operations came in at $0.40, versus $0.27 a year earlier. Revenue was $0, consistent with the company's pre-commercial stage.
The reported loss per share of $0.40 was wider than the analyst consensus estimate of approximately $0.34, reflecting a faster-than-expected rise in expenses. The main driver was a roughly 67% year-over-year increase in R&D costs tied to the continued expansion of the Flamingo-01 Phase III trial. For the first nine months of 2026, the company posted a net loss of $15.42 million (loss per share of $1.05), up from $10.2 million (loss per share of $0.76) in the prior-year period.
The company ended the period with cash and equivalents of about $5.9 million. Management has previously raised substantial doubt about its ability to continue as a going concern, and it continues to rely on at-the-market (ATM) equity offerings — a financing method that sells newly issued shares gradually at prevailing market prices — to support operations.
GLSI shares have historically been sensitive to two factors: progress on the Flamingo-01 trial and the company's financing position. Heading into this report, sentiment was already cautious given the shrinking cash balance and the recurring going-concern language in SEC filings. A wider-than-expected loss per share, combined with a cash position below $6 million, tends to keep investors focused on the likelihood of additional equity issuance through the ATM program. While clinical milestones can drive sharp moves in biotech names, the absence of near-term data in this report shifts attention back to balance-sheet strength and the pace of capital consumption rather than any fundamental revenue story.
Looking ahead, investors should monitor the pace of patient enrollment and site activation in the Flamingo-01 Phase III trial, particularly as the company expands into Europe. Faster enrollment generally translates into higher near-term R&D spending, so the trial's progress will remain closely tied to the company's cash burn.
Cash runway is the central near-term concern. With roughly $5.9 million in cash and a quarterly net loss above $5 million, the company will likely need additional funding to sustain operations. Watch for further ATM sales and any other financing arrangements, as well as their dilutive impact on existing shareholders.
Finally, keep an eye on any management commentary regarding trial timelines, regulatory interactions, and cost controls. Because GLSI is a pre-revenue company, its equity story hinges on clinical execution and its ability to fund development without eroding shareholder value. No near-term data readouts have been announced, so financing updates and enrollment milestones are likely to be the most relevant catalysts in the coming quarters.
In my analysis of clinical-stage names like this, I often turn to Tickeron’s AI-powered tools to quickly filter sector peers and spot patterns in volatility or technical signals. The AI Screener lets me scan thousands of stocks using customizable filters for industry, market cap, and performance metrics, helping surface ideas worth deeper review without manual effort. It has become a practical part of staying on top of biotech developments efficiently.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
GLSI broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GLSI as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for GLSI just turned positive on November 17, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
GLSI moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +49.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.596). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology